Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Sun, Sep 1, 2024
[Archive]
Volume 15, Issue 2 (Spring 2024)
Caspian J Intern Med 2024, 15(2): 202-214 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sheikhi M, Rostami M, Ferns G, Ayatollahi H, Siyadat P, Ayatollahi Y et al . Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis. Caspian J Intern Med 2024; 15 (2) :202-214
URL: http://caspjim.com/article-1-3479-en.html
URL: http://caspjim.com/article-1-3479-en.html
Maryam Sheikhi 
, Mehrdad Rostami , Gordon Ferns , Hossein Ayatollahi , Payam Siyadat , Yasamin Ayatollahi , Zahra Khoshnegah
, Mehrdad Rostami , Gordon Ferns , Hossein Ayatollahi , Payam Siyadat , Yasamin Ayatollahi , Zahra Khoshnegah
Department of Laboratory Hematology and Blood Banking, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran , zkhoshnegah@gmail.com
Abstract: (908 Views)
Background: Although genetic mutations in additional sex-combs-like 1 (ASXL1) are prevalent in acute myeloid leukemia (AML), their exact impact on the AML prognosis remains uncertain. Hence, the present article was carried out to explore the prognostic importance of ASXL1 mutations in AML.
Methods: We thoroughly searched electronic scientific databases to find eligible papers. Twenty-seven studies with an overall number of 8,953 participants were selected for the current systematic review. The hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were extracted from all studies with multivariate or univariate analysis. Pooled HRs and p-values were also calculated as a part of our work.
Results: The pooled HR for OS in multivariable analysis indicated that ASXL1 significantly diminished survival in AML patients (pooled HR: 1.67; 95% CI: 1.342-2.091).
Conclusions: ASXL1 mutations may confer a poor prognosis in AML. Hence, they may be regarded as potential prognostic factors. However, more detailed studies with different ASXL1 mutations are suggested to shed light on this issue.
Methods: We thoroughly searched electronic scientific databases to find eligible papers. Twenty-seven studies with an overall number of 8,953 participants were selected for the current systematic review. The hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were extracted from all studies with multivariate or univariate analysis. Pooled HRs and p-values were also calculated as a part of our work.
Results: The pooled HR for OS in multivariable analysis indicated that ASXL1 significantly diminished survival in AML patients (pooled HR: 1.67; 95% CI: 1.342-2.091).
Conclusions: ASXL1 mutations may confer a poor prognosis in AML. Hence, they may be regarded as potential prognostic factors. However, more detailed studies with different ASXL1 mutations are suggested to shed light on this issue.
Type of Study: Review Article |
Subject:
Hematology
Received: 2022/05/2 | Accepted: 2023/02/26 | Published: 2024/02/21
Received: 2022/05/2 | Accepted: 2023/02/26 | Published: 2024/02/21
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
